Abstract
Cell-to-cell communication is an integral function of multicellular organisms. Many of these signals are received by a myriad of cell-surface receptors that utilize a range of intracellular signaling pathways to communicate this to the nucleus, rapidly impacting on the transcription of target genes in order to elicit the desired response, such as proliferation, differentiation, activation, and survival. Dysregulation of these important signaling pathways, and networks, often lead to pathological conditions due to inappropriate cell responses with negative consequences. The aberrant signaling pathways have been associated with many diseases, including cancer. Cytokines and chemokines convey a multitude of messages to the target cell, many of which are beneficial for cancers and cancer stem cells, such as proliferation, survival and migration. By hijacking this communication network, cancers and cancer stem cells can become invasive and more pathogenic. Furthermore, by using these communication systems, cancer stem cells are able to evade current therapies. Therefore, novel therapies may be developed to break the communication systems of the cancer stem cells. This chapter explores the role of the cytokines TGF-β, TNF-α, IL-1 and IL-6 and chemokine CXCL8 as well as NF-κB and their role in cancer stem cell survival and maintenance. Emerging therapies are beginning to target the cancer stem cell population, either specifically or synergistically with existing therapeutic options. These novel therapies may hold the key to breaking the communication network of cancer stem cells.
Keywords
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Abbas T, Dutta A (2009) p21 in cancer: intricate networks and multiple activities. Nat Rev Cancer 9(6):400–414
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF (2003) Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 100(7):3983–3988
Asiedu MK, Ingle JN, Behrens MD, Radisky DC, Knutson KL (2011) TGFbeta/TNF(alpha)-mediated epithelial-mesenchymal transition generates breast cancer stem cells with a claudin-low phenotype. Cancer Res 71(13):4707–4719
Askmyr M, Agerstam H, Hansen N, Gordon S, Arvanitakis A, Rissler M et al (2013) Selective killing of candidate AML stem cells by antibody targeting of IL1RAP. Blood 121(18):3709–3713
Balkwill F (2009) Tumour necrosis factor and cancer. Nat Rev Cancer 9(5):361–371
Bates RC, Mercurio AM (2003) Tumor necrosis factor-alpha stimulates the epithelial-to-mesenchymal transition of human colonic organoids. Mol Biol Cell 14(5):1790–1800
Baud V, Karin M (2009) Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov 8(1):33–40
Ben Musa R, Usha L, Hibbeln J, Mutlu EA (2014) TNF inhibitors to treat ulcerative colitis in a metastatic breast cancer patient: a case report and literature review. World J Gastroenterol 20(19):5912–5917
Bhola NE, Balko JM, Dugger TC, Kuba MG, Sanchez V, Sanders M et al (2013) TGF-beta inhibition enhances chemotherapy action against triple-negative breast cancer. J Clin Invest 123(3):1348–1358
Biddle A, Mackenzie IC (2012) Cancer stem cells and EMT in carcinoma. Cancer Metastasis Rev 31:285
Biswas SK, Allavena P, Mantovani A (2013) Tumor-associated macrophages: functional diversity, clinical significance, and open questions. Semin Immunopathol 35(5):585–600
Bongartz T, Sutton AJ, Sweeting MJ, Buchan I, Matteson EL, Montori V (2006) Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295(19):2275–2285
Boulay JL, O’Shea JJ, Paul WE (2003) Molecular phylogeny within type I cytokines and their cognate receptors. Immunity 19(2):159–163
Brabletz T (2012) EMT and MET in metastasis: where are the cancer stem cells? Cancer Cell 22(6):699–701
Brown ER, Charles KA, Hoare SA, Rye RL, Jodrell DI, Aird RE et al (2008) A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer. Ann Oncol 19(7):1340–1346
Burton ER, Libutti SK (2009) Targeting TNF-alpha for cancer therapy. J Biol 8(9):85
Chaffer CL, Brueckmann I, Scheel C, Kaestli AJ, Wiggins PA, Rodrigues LO et al (2011) Normal and neoplastic nonstem cells can spontaneously convert to a stem-like state. Proc Natl Acad Sci USA 108(19):7950–7955
Chen L, Fan J, Chen H, Meng Z, Chen Z, Wang P et al (2014) The IL-8/CXCR1 axis is associated with cancer stem cell-like properties and correlates with clinical prognosis in human pancreatic cancer cases. Sci Rep 4:5911
Clevers H (2011) The cancer stem cell: premises, promises and challenges. Nat Med 17(3):313–319
Connolly EC, Freimuth J, Akhurst RJ (2012) Complexities of TGF-beta targeted cancer therapy. Int J Biol Sci 8(7):964–978
Coussens LM, Werb Z (2002) Inflammation and cancer. Nature 420(6917):860–867
Cuzick J, Otto F, Baron JA, Brown PH, Burn J, Greenwald P et al (2009) Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol 10(5):501–507
D’Anello L, Sansone P, Storci G, Mitrugno V, D’Uva G, Chieco P et al (2010) Epigenetic control of the basal-like gene expression profile via Interleukin-6 in breast cancer cells. Mol Cancer 9:300
Derynck R, Zhang YE (2003) Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 425(6958):577–584
Dinarello CA (2010) Why not treat human cancer with interleukin-1 blockade? Cancer Metastasis Rev 29(2):317–329
Dinarello CA (2011) Interleukin-1 in the pathogenesis and treatment of inflammatory diseases. Blood 117(14):3720–3732
Egea V, von Baumgarten L, Schichor C, Berninger B, Popp T, Neth P et al (2011) TNF-alpha respecifies human mesenchymal stem cells to a neural fate and promotes migration toward experimental glioma. Cell Death Differ 18(5):853–863
Ernst M, Oates A, Dunn AR (1996) Gp130-mediated signal transduction in embryonic stem cells involves activation of Jak and Ras/mitogen-activated protein kinase pathways. J Biol Chem 271(47):30136–30143
Fornari F, Milazzo M, Chieco P, Negrini M, Calin GA, Grazi GL et al (2010) MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res 70(12):5184–5193
Gales D, Clark C, Manne U, Samuel T (2013) The chemokine CXCL8 in carcinogenesis and drug response. ISRN Oncol 2013:859154
Ginestier C, Liu S, Diebel ME, Korkaya H, Luo M, Brown M et al (2010) CXCR1 blockade selectively targets human breast cancer stem cells in vitro and in xenografts. J Clin Invest 120(2):485–497
Greten FR, Arkan MC, Bollrath J, Hsu LC, Goode J, Miething C et al (2007) NF-kappaB is a negative regulator of IL-1beta secretion as revealed by genetic and pharmacological inhibition of IKKbeta. Cell 130(5):918–931
Grivennikov SI, Greten FR, Karin M (2010) Immunity, inflammation, and cancer. Cell 140(6):883–899
Gueorguieva I, Cleverly AL, Stauber A, Sada Pillay N, Rodon JA, Miles CP et al (2014) Defining a therapeutic window for the novel TGF-beta inhibitor LY2157299 monohydrate based on a pharmacokinetic/pharmacodynamic model. Br J Clin Pharmacol 77(5):796–807
Guo Y, Xu F, Lu T, Duan Z, Zhang Z (2012) Interleukin-6 signaling pathway in targeted therapy for cancer. Cancer Treat Rev 38(7):904–910
Gupta SC, Patchva S, Aggarwal BB (2013) Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J 15(1):195–218
Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100(1):57–70
Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144(5):646–674
Harrison ML, Obermueller E, Maisey NR, Hoare S, Edmonds K, Li NF et al (2007) Tumor necrosis factor alpha as a new target for renal cell carcinoma: two sequential phase II trials of infliximab at standard and high dose. J Clin Oncol 25(29):4542–4549
Hartnett L, Egan LJ (2012) Inflammation, DNA methylation and colitis-associated cancer. Carcinogenesis 33(4):723–731
Hirsch HA, Iliopoulos D, Tsichlis PN, Struhl K (2009) Metformin selectively targets cancer stem cells, and acts together with chemotherapy to block tumor growth and prolong remission. Cancer Res 69(19):7507–7511
Hussain AR, Ahmed M, Al-Jomah NA, Khan AS, Manogaran P, Sultana M et al (2008) Curcumin suppresses constitutive activation of nuclear factor-kappa B and requires functional Bax to induce apoptosis in Burkitt’s lymphoma cell lines. Mol Cancer Ther 7(10):3318–3329
Iliopoulos D, Hirsch HA, Wang G, Struhl K (2011) Inducible formation of breast cancer stem cells and their dynamic equilibrium with non-stem cancer cells via IL6 secretion. Proc Natl Acad Sci USA 108(4):1397–1402
Ji Y, Zhang W (2010) Th17 cells: positive or negative role in tumor? Cancer Immunol Immunother 59(7):979–987
Jing Y, Han Z, Zhang S, Liu Y, Wei L (2011) Epithelial-mesenchymal transition in tumor microenvironment. Cell Biosci 1:29
Jones SA, Scheller J, Rose-John S (2011) Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling. J Clin Invest 121(9):3375–3383
Joseph JV, Balasubramaniyan V, Walenkamp A, Kruyt FA (2013) TGF-beta as a therapeutic target in high grade gliomas – promises and challenges. Biochem Pharmacol 85(4):478–485
Karin M (2009) NF-kappaB as a critical link between inflammation and cancer. Cold Spring Harb Perspect Biol 1(5):a000141
Karin M, Cao Y, Greten FR, Li ZW (2002) NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer 2(4):301–310
Karin M, Yamamoto Y, Wang QM (2004) The IKK NF-kappa B system: a treasure trove for drug development. Nat Rev Drug Discov 3(1):17–26
Katsuno Y, Lamouille S, Derynck R (2013) TGF-beta signaling and epithelial-mesenchymal transition in cancer progression. Curr Opin Oncol 25(1):76–84
Knupfer H, Preiss R (2007) Significance of interleukin-6 (IL-6) in breast cancer (review). Breast Cancer Res Treat 102(2):129–135
Kobilka BK (2007) G protein coupled receptor structure and activation. Biochim Biophys Acta 1768(4):794–807
Koch U, Krause M, Baumann M (2010) Cancer stem cells at the crossroads of current cancer therapy failures–radiation oncology perspective. Semin Cancer Biol 20(2):116–124
Kong D, Li Y, Wang Z, Sarkar FH (2011) Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: are they cousins or twins? Cancers (Basel) 3(1):716–729
Korkaya H, Liu S, Wicha MS (2011) Regulation of cancer stem cells by cytokine networks: attacking cancer’s inflammatory roots. Clin Cancer Res 17(19):6125–6129
Korkaya H, Kim GI, Davis A, Malik F, Henry NL, Ithimakin S et al (2012) Activation of an IL6 inflammatory loop mediates trastuzumab resistance in HER2+ breast cancer by expanding the cancer stem cell population. Mol Cell 47(4):570–584
Kubiczkova L, Sedlarikova L, Hajek R, Sevcikova S (2012) TGF-beta – an excellent servant but a bad master. J Transl Med 10:183
Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG et al (2012) A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res 72(1):66–75
Lee SH, Hong HS, Liu ZX, Kim RH, Kang MK, Park NH et al (2012) TNFalpha enhances cancer stem cell-like phenotype via Notch-Hes1 activation in oral squamous cell carcinoma cells. Biochem Biophys Res Commun 424(1):58–64
Levina V, Marrangoni AM, DeMarco R, Gorelik E, Lokshin AE (2008) Drug-selected human lung cancer stem cells: cytokine network, tumorigenic and metastatic properties. PLoS One 3(8):e3077
Li CW, Xia W, Huo L, Lim SO, Wu Y, Hsu JL et al (2012a) Epithelial-mesenchymal transition induced by TNF-alpha requires NF-kappaB-mediated transcriptional upregulation of Twist1. Cancer Res 72(5):1290–1300
Li Y, Wang L, Pappan L, Galliher-Beckley A, Shi J (2012b) IL-1b promotes stemness and invasiveness of colon cancer cells through Zeb1 activation. Mol Cancer 11:87
Liang-kuan B, Nan Z, Cheng L, Fu-Ding L, Tian-Xin L, Xu-Jun X et al (2014) Kidney cancer cells secrete IL-8 to activate Akt and promote migration of mesenchymal stem cells. Urol Oncol 32(5):607–612
Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, Monville F et al (2011) Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 71(2):614–624
Liu Z, Bandyopadhyay A, Nichols RW, Wang L, Hinck AP, Wang S et al (2012) Blockade of autocrine TGF-b signaling inhibits stem cell phenotype, survival, and metastasis of murine breast cancer cells. J Stem Cell Res Ther 2(1):1–8
Lu H, Ouyang W, Huang C (2006) Inflammation, a key event in cancer development. Mol Cancer Res 4(4):221–233
Mani SA, Guo W, Liao MJ, Eaton EN, Ayyanan A, Zhou AY et al (2008) The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 133(4):704–715
Massague J (2000) How cells read TGF-beta signals. Nat Rev Mol Cell Biol 1(3):169–178
Mayol JF, Loeuillet C, Herodin F, Wion D (2009) Characterisation of normal and cancer stem cells: one experimental paradigm for two kinds of stem cells. Bioessays 31(9):993–1001
Medema JP (2013) Cancer stem cells: the challenges ahead. Nat Cell Biol 15(4):338–344
Mori Y, Ishida W, Bhattacharyya S, Li Y, Platanias LC, Varga J (2004) Selective inhibition of activin receptor-like kinase 5 signaling blocks profibrotic transforming growth factor beta responses in skin fibroblasts. Arthritis Rheum 50(12):4008–4021
Morris JC, Tan AR, Olencki TE, Shapiro GI, Dezube BJ, Reiss M et al (2014) Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFbeta) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma. PLoS One 9(3):e90353
Mukaida N, Sasakki S, Popivanova BK (2011) Tumor necrosis factor (TNF) and chemokines in colitis-associated cancer. Cancers (Basel) 3(3):2811–2826
Notara M, Shortt AJ, Galatowicz G, Calder V, Daniels JT (2010) IL6 and the human limbal stem cell niche: a mediator of epithelial-stromal interaction. Stem Cell Res 5(3):188–200
Padua D, Massague J (2009) Roles of TGFbeta in metastasis. Cell Res 19(1):89–102
Perrot CY, Javelaud D, Mauviel A (2013) Overlapping activities of TGF-beta and Hedgehog signaling in cancer: therapeutic targets for cancer treatment. Pharmacol Ther 137(2):183–199
Prasad S, Ravindran J, Aggarwal BB (2010) NF-kappaB and cancer: how intimate is this relationship. Mol Cell Biochem 336(1–2):25–37
Rider P, Carmi Y, Voronov E, Apte RN (2013) Interleukin-1a. Semin Immunol 25(6):430–438
Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M et al (2007) IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 117(12):3988–4002
Schillace RV, Skinner AM, Pommier RF, O’Neill S, Muller PJ, Naik AM et al (2014) Estrogen receptor, progesterone receptor, interleukin-6 and interleukin-8 are variable in breast cancer and benign stem/progenitor cell populations. BMC Cancer 14(1):733
Schlingensiepen KH, Jaschinski F, Lang SA, Moser C, Geissler EK, Schlitt HJ et al (2011) Transforming growth factor-beta 2 gene silencing with trabedersen (AP 12009) in pancreatic cancer. Cancer Sci 102(6):1193–1200
Schroeder RL, Stevens CL, Sridhar J (2014) Small molecule tyrosine kinase inhibitors of ErbB2/HER2/Neu in the treatment of aggressive breast cancer. Molecules 19(9):15196–15212
Sethi G, Sung B, Aggarwal BB (2008) TNF: a master switch for inflammation to cancer. Front Biosci 13:5094–5107
Shackleton M (2010) Normal stem cells and cancer stem cells: similar and different. Semin Cancer Biol 20(2):85–92
Shigdar S, Li Y, Bhattacharya S, O’Connor M, Pu C, Lin J et al (2014) Inflammation and cancer stem cells. Cancer Lett 345(2):271–278
Simon MC, Keith B (2008) The role of oxygen availability in embryonic development and stem cell function. Nat Rev Mol Cell Biol 9(4):285–296
Singh A, Settleman J (2010) EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 29(34):4741–4751
Singh S, Singh AP, Sharma B, Owen LB, Singh RK (2010) CXCL8 and its cognate receptors in melanoma progression and metastasis. Future Oncol 6(1):111–116
Singh JK, Farnie G, Bundred NJ, Simoes BM, Shergill A, Landberg G et al (2013) Targeting CXCR1/2 significantly reduces breast cancer stem cell activity and increases the efficacy of inhibiting HER2 via HER2-dependent and -independent mechanisms. Clin Cancer Res 19(3):643–656
Skov L, Beurskens FJ, Zachariae CO, Reitamo S, Teeling J, Satijn D et al (2008) IL-8 as antibody therapeutic target in inflammatory diseases: reduction of clinical activity in palmoplantar pustulosis. J Immunol 181(1):669–679
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 235(4785):177–182
Soria G, Ofri-Shahak M, Haas I, Yaal-Hahoshen N, Leider-Trejo L, Leibovich-Rivkin T et al (2011) Inflammatory mediators in breast cancer: coordinated expression of TNFalpha & IL-1beta with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer 11:130
Storci G, Sansone P, Mari S, D’Uva G, Tavolari S, Guarnieri T et al (2010) TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype. J Cell Physiol 225(3):682–691
Tanno T, Matsui W (2011) Development and maintenance of cancer stem cells under chronic inflammation. J Nippon Med Sch 78(3):138–145
Tornatore L, Sandomenico A, Raimondo D, Low C, Rocci A, Tralau-Stewart C et al (2014) Cancer-selective targeting of the NF-kappaB survival pathway with GADD45beta/MKK7 inhibitors. Cancer Cell 26(4):495–508
Turzanski J, Grundy M, Russell NH, Pallis M (2004) Interleukin-1b maintains an apoptosis-resistant phenotype in the blast cells of acute myeloid leukaemia via multiple pathways. Leukemia 18(10):1662–1670
Wang L, Liu Z, Balivada S, Shrestha T, Bossmann S, Pyle M et al (2012) Interleukin-1b and transforming growth factor-b cooperate to induce neurosphere formation and increase tumorigenicity of adherent LN-229 glioma cells. Stem Cell Res Ther 3(1):5
Wang L, Zhao Y, Liu Y, Akiyama K, Chen C, Qu C et al (2013) IFN-gamma and TNF-alpha synergistically induce mesenchymal stem cell impairment and tumorigenesis via NFkappaB signaling. Stem Cells 31(7):1383–1395
Waugh DJ, Wilson C (2008) The interleukin-8 pathway in cancer. Clin Cancer Res 14(21):6735–6741
Weber A, Wasiliew P, Kracht M (2010) Interleukin-1 (IL-1) pathway. Sci Signal 3(105):cm1
Werman A, Werman-Venkert R, White R, Lee JK, Werman B, Krelin Y et al (2004) The precursor form of IL-1a is an intracrine proinflammatory activator of transcription. Proc Natl Acad Sci USA 101(8):2434–2439
Yamamoto M, Taguchi Y, Ito-Kureha T, Semba K, Yamaguchi N, Inoue J (2013) NF-kappaB non-cell-autonomously regulates cancer stem cell populations in the basal-like breast cancer subtype. Nat Commun 4:2299
Yin G, Chen R, Alvero AB, Fu HH, Holmberg J, Glackin C et al (2010) TWISTing stemness, inflammation and proliferation of epithelial ovarian cancer cells through MIR199A2/214. Oncogene 29(24):3545–3553
Zhang J, Wu H, Li P, Zhao Y, Liu M, Tang H (2014) NF-kappaB-modulated miR-130a targets TNF-alpha in cervical cancer cells. J Transl Med 12:155
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2015 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Liongue, C., Ward, A.C., Duan, W., Shigdar, S. (2015). Cytokine Networks and Cancer Stem Cells. In: Babashah, S. (eds) Cancer Stem Cells: Emerging Concepts and Future Perspectives in Translational Oncology. Springer, Cham. https://doi.org/10.1007/978-3-319-21030-8_3
Download citation
DOI: https://doi.org/10.1007/978-3-319-21030-8_3
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-21029-2
Online ISBN: 978-3-319-21030-8
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)